Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Randomized Treatment Period: Vandetanib
Total, all-cause mortality	Randomized Treatment Period: Placebo
Total, all-cause mortality	Open-Label Treatment Period: Vandetanib/Vandetanib
Total, all-cause mortality	Open-Label Treatment Period: Placebo/Vandetanib
Total, other adverse events	Randomized Treatment Period: Vandetanib	111	117
Total, other adverse events	Randomized Treatment Period: Placebo	87	118
Total, other adverse events	Open-Label Treatment Period: Vandetanib/Vandetanib	9	23
Total, other adverse events	Open-Label Treatment Period: Placebo/Vandetanib	62	74
Total, serious adverse events	Randomized Treatment Period: Vandetanib	37	117
Total, serious adverse events	Randomized Treatment Period: Placebo	19	118
Total, serious adverse events	Open-Label Treatment Period: Vandetanib/Vandetanib	7	23
Total, serious adverse events	Open-Label Treatment Period: Placebo/Vandetanib	24	74

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01876784/event-totals